Bank Julius Baer & Co
PRLD icon

Bank Julius Baer & Co’s Prelude Therapeutics PRLD Stock Holding History

Bank Julius Baer & Co’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17,312
Closed -$750K – 859
2021
Q1 		$750K Buy
+17,312
New +$1.15M 0.01% 378

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Bank Julius Baer & Co's PRLD Position: Q2 2021 in Review

Bank Julius Baer & Co sold out of Prelude Therapeutics (PRLD) in Q2 2021, closing a stake of 17,312 shares — an estimated $750K sold.

Bank Julius Baer & Co first reported a position in PRLD in Q1 2021 and held it in 1 quarter. The position peaked at $750K in Q1 2021. 57 funds tracked by Wall St. Rank hold PRLD as of Q2 2021.

  • Bank Julius Baer & Co reported no remaining Prelude Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Bank Julius Baer & Co sold 17,312 Prelude Therapeutics shares in Q2 2021, an estimated $750K.
  • Bank Julius Baer & Co first reported a position in Prelude Therapeutics in Q1 2021 and held it in 1 quarter.
  • Bank Julius Baer & Co's Prelude Therapeutics position peaked at $750K in Q1 2021.
  • 57 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2021.

Based on Bank Julius Baer & Co's 13F filing for Q2 2021, filed 23 Jul 2021.